case_images: PMC11322109_01
case_images: Creatine kinase and myoglobin concentration curve case 1.
case_images: fpsyt-15-1450092-g001.jpg
case_images: PMC11322109_01_fpsyt-15-1450092-g001.jpg
case_images: f1
case_images: The development of creatine kinase and myoglobin can be seen in  Figure 1 . These measures resulted in a decrease in CK and myoglobin (see  Figure 1 ).
case_images: PMC11322109_02
case_images: Creatine kinase and myoglobin concentration curve case 2.
case_images: fpsyt-15-1450092-g002.jpg
case_images: PMC11322109_02_fpsyt-15-1450092-g002.jpg
case_images: f2
case_images: Further close laboratory checks revealed increasingly rising CK, CK-MB, and myoglobin values, as well as poorer kidney values (Cystatin C 0,98 - 1,12 mg/l) consistent with rhabdomyolysis (see  Figure 2 ). The liver values had also fallen significantly with only a minimal transaminase increase of 52U/l of AST 16 days after ending esketamine therapy (see  Figure 2 ).